UOB Kay Hian Lowers ALI HEALTH Price Target to HK$6, Trims Earnings Forecast on Increased Innovation Drug and AI Investments

Stock News04-14

UOB Kay Hian has released a research report stating that ALI HEALTH has reaffirmed its revenue growth target for fiscal year 2026 at 10% to 15% annually. However, the company has revised its adjusted net profit growth target down from 20%-30% to 10%-20%, citing increased investments in innovative drugs and artificial intelligence. The brokerage has consequently lowered its forecast for the group's adjusted net profit growth in FY2026 from 25% to 15%. Despite this adjustment, UOB Kay Hian maintains its projections for a compound annual growth rate of 13% for revenue and 24% for adjusted net profit from fiscal 2026 to 2028. This sustained growth is anticipated to be driven by strong momentum in innovative drugs, deeper synergies with Alibaba, and the expanding application of AI technologies. The firm has reiterated its "Buy" rating on the stock but reduced the target price from HK$7.8 to HK$6.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1143388486?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 16:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143388486","market":"fut","top_or_hot":-1,"title":"UOB Kay Hian Lowers ALI HEALTH Price Target to HK$6, Trims Earnings Forecast on Increased Innovation Drug and AI Investments","media":"Stock News","content":"<p>UOB Kay Hian has released a research report stating that ALI HEALTH has reaffirmed its revenue growth target for fiscal year 2026 at 10% to 15% annually. However, the company has revised its adjusted net profit growth target down from 20%-30% to 10%-20%, citing increased investments in innovative drugs and artificial intelligence. The brokerage has consequently lowered its forecast for the group's adjusted net profit growth in FY2026 from 25% to 15%. Despite this adjustment, UOB Kay Hian maintains its projections for a compound annual growth rate of 13% for revenue and 24% for adjusted net profit from fiscal 2026 to 2028. This sustained growth is anticipated to be driven by strong momentum in innovative drugs, deeper synergies with Alibaba, and the expanding application of AI technologies. The firm has reiterated its \"Buy\" rating on the stock but reduced the target price from HK$7.8 to HK$6.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UOB Kay Hian Lowers ALI HEALTH Price Target to HK$6, Trims Earnings Forecast on Increased Innovation Drug and AI Investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUOB Kay Hian Lowers ALI HEALTH Price Target to HK$6, Trims Earnings Forecast on Increased Innovation Drug and AI Investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-14 16:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UOB Kay Hian has released a research report stating that ALI HEALTH has reaffirmed its revenue growth target for fiscal year 2026 at 10% to 15% annually. However, the company has revised its adjusted net profit growth target down from 20%-30% to 10%-20%, citing increased investments in innovative drugs and artificial intelligence. The brokerage has consequently lowered its forecast for the group's adjusted net profit growth in FY2026 from 25% to 15%. Despite this adjustment, UOB Kay Hian maintains its projections for a compound annual growth rate of 13% for revenue and 24% for adjusted net profit from fiscal 2026 to 2028. This sustained growth is anticipated to be driven by strong momentum in innovative drugs, deeper synergies with Alibaba, and the expanding application of AI technologies. The firm has reiterated its \"Buy\" rating on the stock but reduced the target price from HK$7.8 to HK$6.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1617","symbol_name":"AI医疗","start_time":0,"source_url":"","article_id":"1143388486","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143388486","pubTimestamp":1776155107,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UOB Kay Hian has released a research report stating that ALI HEALTH has reaffirmed its revenue growth target for fiscal year 2026 at 10% to 15% annually. However, the company has revised its adjusted...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159992":"创新药","BK1617":"AI医疗","06978":"永泰生物-B","BK1610":"ETF&股票定投概念","BK1161":"生物科技","BK1615":"港股-互联网","BK1584":"蚂蚁金服概念","BK1571":"互联网医疗","AGIX":"通用人工智能 ETF-AGIX","BK1515":"抗疫概念","BK1574":"生物医药B类股","BK1591":"就地过年概念","BK1247":"药品零售","00241":"阿里健康","ARTY":"ISHARES FUTURE AI & TECH ETF","BK1502":"双十一","AIPO":"Defiance AI and Power Infrastructure ETF","BK1501":"阿里概念股","BK1589":"北水核心资产","BK1142":"互联网与直销零售","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK1189":"医疗保健技术","EWH":"香港ETF-iShares MSCI"},"translate_title":"大华继显将阿里健康目标价下调至6港元，因创新药和人工智能投资增加而下调盈利预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"06978":1,"AIPO":1,"CHAT":1,"ARTY":1,"EWH":1,"00241":1,"AGIX":1},"content_text":"UOB Kay Hian has released a research report stating that ALI HEALTH has reaffirmed its revenue growth target for fiscal year 2026 at 10% to 15% annually. However, the company has revised its adjusted net profit growth target down from 20%-30% to 10%-20%, citing increased investments in innovative drugs and artificial intelligence. The brokerage has consequently lowered its forecast for the group's adjusted net profit growth in FY2026 from 25% to 15%. Despite this adjustment, UOB Kay Hian maintains its projections for a compound annual growth rate of 13% for revenue and 24% for adjusted net profit from fiscal 2026 to 2028. This sustained growth is anticipated to be driven by strong momentum in innovative drugs, deeper synergies with Alibaba, and the expanding application of AI technologies. The firm has reiterated its \"Buy\" rating on the stock but reduced the target price from HK$7.8 to HK$6.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1143388486","isCrawlerRequest":true}